Asset
OBEXELIMAB
Zenas BioPharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05662241 | phase3 | active_not_recruiting | 2023-01-09 | 2025-11-13 | Zenas BioPharma (USA), LLC | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease |
| NCT06564311 | phase2 | active_not_recruiting | 2024-08-26 | 2025-08-28 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) |
| NCT06559163 | phase2 | active_not_recruiting | 2024-09-17 | 2026-09-01 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus |
| NCT05786573 | phase3 | active_not_recruiting | 2023-09-25 | 2026-06-30 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) |
FDA applications (0)
This company has no applications containing this asset.